{"id":"W4390790402","doi":"10.1111/jdv.19701","title":"Tofacitinib efficacy, patient‐reported outcomes and safety in patients with psoriasis and a medical history of psoriatic arthritis: Pooled analysis of two Phase <scp>III</scp> studies","year":2024,"lang":"en","type":"letter","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Memorial University of Newfoundland; Pfizer (Canada); Probity Medical Research; University of Toronto","funders":"Medical Research Council; Manchester Biomedical Research Centre; LEO Pharma; Sun Pharma; Bausch Health; Astellas Pharma; National Institute for Health and Care Research; Valeant Pharmaceuticals International; Amgen; Pfizer; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Tofacitinib; Discontinuation; Internal medicine; Psoriatic arthritis; Janus kinase inhibitor; Placebo; Adverse effect; Psoriasis; Randomized controlled trial; Physical therapy; Rheumatoid arthritis; Dermatology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01994582,0.001968945,0.009770114,0.002996697,0.000332166,0.002525891,0.0008935435,0.001432503,0.002386204],"category_scores_gemma":[0.02247438,0.0008427335,0.02390114,0.004095279,0.000420584,0.001161658,0.001152155,0.001340577,0.000241299],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008646642,"about_ca_system_score_gemma":0.001016832,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001688162,"about_ca_topic_score_gemma":0.003720996,"domain_scores_codex":[0.9874296,0.00629645,0.003142304,0.001317367,0.00151366,0.0003006466],"domain_scores_gemma":[0.9831569,0.009468745,0.004596641,0.0009673076,0.001491823,0.0003186096],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.04869567,0.00007264618,0.018718,0.02872885,0.8793074,0.0001021114,0.0000571875,0.0007407268,0.0005540818,0.00009570503,0.001566977,0.02136061],"study_design_scores_gemma":[0.01999032,0.002628196,0.06307136,0.002610304,0.9057698,0.0003150218,0.0000718782,0.0006734383,0.0003718007,0.0004058431,0.004007548,0.0000843512],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.129822,0.8514103,0.002061824,0.0006123293,0.0004812434,0.001042543,0.01220457,0.0001087268,0.002256523],"genre_scores_gemma":[0.8425128,0.1390523,0.002504776,0.001194117,0.0009139303,0.002105971,0.01095068,0.00006755185,0.0006978413],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.01994582,"threshold_uncertainty_score":0.1054849,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01815601356243269,"score_gpt":0.2660924596037756,"score_spread":0.2479364460413429,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}